Evaluating the effects of hexavalent chromium on uterine vascular remodeling
评估六价铬对子宫血管重塑的影响
基本信息
- 批准号:10581242
- 负责人:
- 金额:$ 22.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAdverse effectsAffectAgeApoptosisAreaArteriesBirth RateBloodBlood VesselsCarcinogensCellsChemical ExposureChildChromium CompoundsClinical DataCollagenCommunitiesComplexCytokeratinDataDatabasesDiameterDiseaseDoseElastinEndocrine DisruptorsEndothelial CellsEndotheliumEnvironmental ExposureEuthanasiaExperimental DesignsExposure toExtracellular MatrixExtracellular Matrix ProteinsFemaleFetal DevelopmentFetal GrowthFetal Growth RetardationFetal ResorptionFetal WeightFetusGrantGrowth FactorHealthHeavy MetalsHigh-Risk PregnancyHospital RecordsHumanIndividualInfantInfertilityInterstitial CollagenaseInvadedLabelLitter SizeMalignant NeoplasmsMediatingMichiganModelingMolecularNewborn InfantNutrientOutcomeOxidative StressPTK2 genePathway interactionsPatternPerfusionPersonsPlacentaPlacentationPotassiumPredispositionPregnancyPregnancy OutcomePregnancy lossPregnant WomenPremature BirthPremature LaborProteinsRattusRelaxationReportingRoleSTAT1 geneSTAT3 geneShapesSignal PathwaySignaling MoleculeSiteSpiral Artery of the EndometriumSpontaneous abortionStat5 proteinThickTimeUnited StatesUnited States National Institutes of HealthUterusVascular Smooth MuscleVascular remodelingVulnerable PopulationsWomanabortionchromium hexavalent ioncontaminated waterearly pregnancyepidemiologic dataexperienceexperimental groupfetalhuman femaleimmunocytochemistryindexinginnovationmalenovelpregnancy disorderpregnancy healthpregnantprematurepressurepupreproductiveresponsespatiotemporaltrophoblastwater qualityworking group
项目摘要
PROJECT SUMMARY
The United States is one of the world’s leading producers of chromium compounds. According to the National
Tap Water quality database and Environmental Working Group report, ~74 million people in the U.S in nearly
7,000 communities drink water contaminated with hexavalent chromium, Cr(VI), and they are predisposed to
various health problems including infertility, pre-term labor, pre-mature abortion, intrauterine fetal growth
restriction, and cancers. A study was conducted using data released from the hospital records of newborn babies
and pregnant women from Willits, CA, exposed to Cr(VI). For the first time, the detrimental reproductive effects
from non-occupational Cr(VI) exposure in human females and their infants was reported in the U.S. Our study
involving the human placenta reported a positive correlation between Cr accumulation in the term placenta (from
Michigan women) and increased oxidative stress. However, how Cr(VI) causes abnormal placental development,
and pregnancy disorders is unknown. The uterine spiral artery is extensively remodeled to deliver a sufficient
supply of maternal blood and nutrients to the developing fetus. Abnormal uterine spiral artery remodeling
adversely affects pregnancy. The current study hypothesizes that Cr(VI) disrupts uterine spiral artery remodeling
by inhibiting trophoblast cell invasion and altering growth factor(s)-mediated signaling pathways. For the first
time, our preliminary study demonstrates Cr(VI)-induced thickness of uterine artery wall and narrowing of the
artery lumen. Cr(VI) inhibited trophoblast cell invasion into the uterine-fetal interface. To conduct the current
project, timed pregnant rats (8-10 wk of age) will be divided into four experimental groups: Control (n=10), Cr(VI)
- 0.1 ppm (n=10), Cr(VI) - 1.0 ppm (n=10), and Cr(VI) - 5.0 ppm (n=10), and exposed to respective doses of
potassium dichromate (Cr(VI)) from GD 9.5 to 12.5 and euthanized on GD18.5. AIM-1 will determine the
placental and fetal weight, resorption sites, the number of male and female pups, placentas shape, and live and
dead pups. Effects of Cr(VI) exposure on spatio-temporal expression of signaling molecules in regulating
trophoblast invasion. AIM-2 will identify the mechanism of Cr(VI) on the myogenic response of the uterine main
artery and its extracellular matrix. Uterine main arteries will be dissected from the pregnant rats treated with
Cr(VI). The contractile responses, endothelial-dependent relaxation responses, active pressure
responses, internal and external diameter, wall thickness, cross-sectional area, and wall strain will be calculated
using pressure and wire myographs. In Study 2b, the extracellular matrix (ECM) proteins network of the uterine
artery will be determined. The current study is innovative to fill the gap in understanding the role of Cr(VI) in
altering uterine vascular adaptation during pregnancy. These findings will help regulate Cr(VI) exposure in
pregnant women since they are vulnerable to EDCs’ exposure.
项目概要
据国家统计局称,美国是世界领先的铬化合物生产国之一。
自来水质量数据库和环境工作组报告显示,美国约 7400 万人几乎
7,000 个社区饮用被六价铬 (Cr(VI)) 污染的水,他们很容易
各种健康问题,包括不孕、早产、早产、胎儿宫内生长
使用新生儿医院记录中发布的数据进行了一项研究。
来自加利福尼亚州威利茨的孕妇首次接触六价铬,对生殖产生不健康的影响。
美国报告了人类女性及其婴儿非职业性 Cr(VI) 暴露的情况。我们的研究
涉及人类胎盘的研究报告称,足月胎盘中 Cr 的积累之间存在正相关性(来自
密歇根州女性)和氧化应激增加然而,Cr(VI)如何导致胎盘发育异常,
子宫螺旋动脉在很大程度上被重塑以提供足够的血液。
向发育中的胎儿供应母体血液和营养物质。子宫螺旋动脉重塑异常。
目前的研究表明 Cr(VI) 会破坏子宫螺旋动脉重塑。
首先通过抑制滋养层细胞侵袭和改变生长因子介导的信号通路。
当时,我们的初步研究表明 Cr(VI) 引起子宫动脉壁增厚和狭窄
Cr(VI) 抑制滋养层细胞侵入子宫-胎儿界面。
项目中,定时怀孕大鼠(8-10周龄)将被分为四个实验组:对照组(n=10)、Cr(VI)
- 0.1 ppm (n=10)、Cr(VI) - 1.0 ppm (n=10) 和 Cr(VI) - 5.0 ppm (n=10),并暴露于相应剂量的
GD 9.5 至 12.5 的重铬酸钾 (Cr(VI)) 并在 AIM-1 上安乐死将确定。
胎盘和胎儿的重量、吸收部位、雄性和雌性幼崽的数量、胎盘形状以及活体和
Cr(VI) 暴露对调节信号分子时空表达的影响。
AIM-2 将确定 Cr(VI) 对子宫主肌生成反应的机制。
将从经处理的怀孕大鼠中解剖子宫主动脉及其细胞外基质。
Cr(VI)。收缩反应、内皮依赖性舒张反应、主动压力。
将计算响应、内径和外径、壁厚、横截面积和壁应变
在研究 2b 中,使用压力和线肌动描记器观察子宫的细胞外基质 (ECM) 蛋白网络。
目前的研究具有创新性,填补了了解 Cr(VI) 在动脉中的作用的空白。
这些发现将有助于调节妊娠期间的子宫血管适应。
孕妇,因为她们容易接触 EDC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sakhila Banu其他文献
Sakhila Banu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sakhila Banu', 18)}}的其他基金
Mechanism of Prenatal Chromium-VI Exposure and Germ Cell Apoptosis in the Ovary
产前六价铬暴露与卵巢生殖细胞凋亡的机制
- 批准号:
9207457 - 财政年份:2016
- 资助金额:
$ 22.78万 - 项目类别:
Chromium VI-induced toxicity on Female Reproductive Function
六价铬对女性生殖功能的毒性
- 批准号:
8177399 - 财政年份:2011
- 资助金额:
$ 22.78万 - 项目类别:
Chromium VI-induced toxicity on Female Reproductive Function
六价铬对女性生殖功能的毒性
- 批准号:
8320185 - 财政年份:2011
- 资助金额:
$ 22.78万 - 项目类别:
Effects of Lactational Exposure to Chromium (VI) on Ovarian Development
哺乳期接触铬 (VI) 对卵巢发育的影响
- 批准号:
7882642 - 财政年份:2009
- 资助金额:
$ 22.78万 - 项目类别:
Effects of Lactational Exposure to Chromium (VI) on Ovarian Development
哺乳期接触铬 (VI) 对卵巢发育的影响
- 批准号:
7586930 - 财政年份:2009
- 资助金额:
$ 22.78万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 22.78万 - 项目类别:
A Nanocarrier Platform for Targeting Schlemm's Canal Cells
用于靶向施累姆氏管细胞的纳米载体平台
- 批准号:
10539739 - 财政年份:2022
- 资助金额:
$ 22.78万 - 项目类别:
A Nanocarrier Platform for Targeting Schlemm's Canal Cells
用于靶向施累姆氏管细胞的纳米载体平台
- 批准号:
10705690 - 财政年份:2022
- 资助金额:
$ 22.78万 - 项目类别:
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence
纤溶酶原激活剂抑制剂 1 在血管平滑肌细胞硬化和衰老中的作用
- 批准号:
10259921 - 财政年份:2021
- 资助金额:
$ 22.78万 - 项目类别:
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence
纤溶酶原激活剂抑制剂 1 在血管平滑肌细胞硬化和衰老中的作用
- 批准号:
10512042 - 财政年份:2021
- 资助金额:
$ 22.78万 - 项目类别: